October 23, 2024- Abbott announced financial results for the third quarter, which ended Sept. 30, 2024. In September, Abbott announced the U.S. launch of Lingo™, the company’s first continuous glucose monitoring system available without a prescription and designed for people interested in improving their overall health and wellness, as well as a partnership with the Big Ten Conference® to conduct a nationwide blood donation competition to help increase the U.S. blood supply. Third-quarter GAAP diluted EPS of $0.94 and adjusted diluted EPS of $1.21, which excludes specified items. Abbott maintains its full-year 2024 organic sales growth guidance range of 9.5% to 10.0%, excluding COVID-19 testing-related sales.